Compare Petróleo Brasileiro SA (PBR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Tango Therapeutics Inc. — how do they compare? Petróleo Brasileiro SA trades at $25.83 (market cap $157.24B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Petróleo Brasileiro SA is far larger — about 41.9× Tango Therapeutics Inc.'s market cap, and Petróleo Brasileiro SA pays a 6.57% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 26 Days and Tango Therapeutics Inc. for 0 Days on average.
| PBR | TNGX | |
|---|---|---|
Market Cap | $157.24B | $3.75B |
Volume | 17,564,454 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $25.94 | $32.90 |
52-Week Low | $11.54 | $7.50 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $217.66B | $2.77B |
Dividend Yield | 6.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $25.50, up 0.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings that beat estimates, with net income nearly doubling year-over-year on record production. Recent news highlights a new oil discovery off Amapa and a 22-year LNG supply deal with Cheniere Energy, supporting long-term growth prospects.
PBR presents a compelling value with a low P/E of 6.44 and robust profitability, including a 30.77% ROE. However, the stock trades above the analyst consensus price target of $22.33, and net cash flow turned negative in 2026. Key risks include political interference in Brazil, volatile oil prices, and execution challenges in new projects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
